Navigation Links
ShangPharma Announces Second Quarter 2011 Results
Date:8/22/2011

stimate," "intend," "plan," "believe," "likely to" or other similar expressions. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. Among other things, the section titled "Full Year 2011 Guidance" and quotations from management in this press release, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its reports filed or furnished with the U.S. Securities and Exchange Commission, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements and are subject to change, and such change may be material and may have a material adverse effect on the Company's financial condition and results of operations for one or more periods. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained, either expressly or impliedly, in any of the forward-looking statements in this press release. The Company expects to face potential risks and uncertainties related to its ability to, among other things, attract, train, motivate and retain skilled scientists; diversify its customer base and adapt to potential loss of sales to, or significant reduction in orders from, any of its major customers; adapt its business to industry trends, such as fluctuations in the R&D budgets of pharmaceutical and biotechnology industry participants; protect the intellectual property rights of its customers; comply with applicable regulations and industry standards; compe
'/>"/>
SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. ShangPharma Corporation Named a Top Ten Chinese Outsourcing Enterprise
2. ShangPharma Announces First Quarter 2011 Results
3. ShangPharma Corp. to Announce Fourth Quarter and Full Year 2010 Financial Results on March 15, 2011
4. Stem Cell Assurance, Inc. Announces Change of Name to BioRestorative Therapies, Inc.
5. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
6. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
7. ACMG Announces New Online Live Learning Center: Will Bring Genetics and Genomics Education to Varied Health Professionals
8. Neurologix Announces Second Quarter 2011 Financial Results
9. Bion Announces New U.S. Patent for Phosphorus Removal
10. ViaCyte Announces Executive Management Changes
11. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... and Companies" to their offering. ... variations, development of sequencing technologies, and their applications. ... well as companies developing them. Various applications of ...
(Date:9/2/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report "Biomarkers - ... This report follows the broad definition ... be objectively measured and evaluated as an indicator ... as pharmacological responses to a therapeutic intervention. Tests ...
(Date:9/2/2015)... , September 2, 2015 Biovista ... winners of the 2015 BeHEARD science challenge, a global ... rare disease researchers, access to the latest life science ... drug repositioning and pathway analytics capability to support ... Foundation in the study of Niemann-Pick Disease Type A ...
(Date:9/2/2015)... Australian prostate cancer technology company Minomic International Ltd has ... science that uses its patented antibody. The ... cancer diagnostic test known as MiCheck® next year, was ... peer-reviewed Australian Museum Eureka Science Prize for Excellence ... is awarded for ground breaking research that has only ...
Breaking Biology Technology:Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3
... McGown, Ph.D. , Molecular Devices Corporation. 7/99 , ... , the first microplate reader equipped with a ... was also the first microplate reader capable of measuring ... microplate reader from a limited colorimetric filterbased instrument to ...
... Yan Zhang, Molecular Devices Corporation, 1311 Orleans Dr., Sunnyvale, CA 94089. , ... INTRODUCTION , ... Quantitation Kit from Molecular Probes in the Gemini XS, Gemini EM and ... from Molecular Devices. This assay is much more sensitive than traditional photometer ...
... Assay , Uses High Efficiency Fluorescence Polarization (HEFP) detection method ... extract and enzyme preparations , Requires no separation or wash ... , Introduction , ... Cyclic adenosine monophosphate (cAMP) is a second messenger involved in ...
Cached Biology Technology:UV Absorbance Measurements in SpectraMax Microplate Spectrophotometers MaxLine Application Note #32) 2UV Absorbance Measurements in SpectraMax Microplate Spectrophotometers MaxLine Application Note #32) 3UV Absorbance Measurements in SpectraMax Microplate Spectrophotometers MaxLine Application Note #32) 4UV Absorbance Measurements in SpectraMax Microplate Spectrophotometers MaxLine Application Note #32) 5UV Absorbance Measurements in SpectraMax Microplate Spectrophotometers MaxLine Application Note #32) 6Using the NanoOrange protein kit in the Gemini XS, Gemini EM and SpectraMax M2 microplate readers (MaxLine Application Note #22) 2Using the NanoOrange protein kit in the Gemini XS, Gemini EM and SpectraMax M2 microplate readers (MaxLine Application Note #22) 3Using the NanoOrange protein kit in the Gemini XS, Gemini EM and SpectraMax M2 microplate readers (MaxLine Application Note #22) 4cAMP DataFile: Homogenous Cyclic AMP detection using High Efficiency Fluorescence Polarization 2cAMP DataFile: Homogenous Cyclic AMP detection using High Efficiency Fluorescence Polarization 3
(Date:8/12/2015)... Calif. , Aug. 12, 2015  Synaptics ... of human interface solutions, today announced that four ... announced Match-in-Sensor solution, have officially been named FIDO ... As part of the certification, Synaptics, Natural ID™ ... 1.0 Universal Authentication Framework (UAF) standard and are ...
(Date:8/10/2015)... Germany , August 10, 2015 ... in Eye Tracking Technology for more than two decades, ... Platform for integration into all consumer display formats. The ... seamless integration of eye tracking into consumer tablets, laptops, ... reality smart glasses. Omnivision,s leading sensor technology contributes to ...
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2
... in German . When someone,s knee ... has been so badly damaged that the bones rub together ... cartilage tissue artificially so that patients with such knee problems ... to make tendons and blood vessels in the laboratory. The ...
... symptoms appear for someone to die from bacterial meningitis. ... of Nottingham have finally discovered how the deadly meningococcal ... defence mechanism and attack the brain. The ... meningitis and could save the lives of hundreds of ...
... ExcellGene SA, Monthey and Adolf Kühner AG, Birsfelden announce ... development of a revolutionary cell culture technology for scale ... As part of a long-term partnership the two companies ... task of growing mammalian cells for the production of ...
Cached Biology News:Non-wovens as scaffolds for artificial tissue 2Breakthrough in the treatment of bacterial meningitis 2ExcellGene and Khner achieved milestone in development of novel 250 Liter mammalian cell culture bioreactors 2ExcellGene and Khner achieved milestone in development of novel 250 Liter mammalian cell culture bioreactors 3
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... for covering tissue sections and cell preparations immunohistochemically ... insoluble end products. UltraMount Plus can ... or AEC that require an aqueous mounting medium, ... No heating is required prior to use. This ...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... Buffer III is intented ... of PBMCs (or lysed ... for intracellular kinases and ... Applications: Intracellular Staining ...
Biology Products: